Evidence map›Paper›PMID 40586049›Full record

ArticleClinical case reports2025

Innovative Use of Fostamatinib in Managing Refractory Immune Thrombocytopenia in an HIV-Positive Patient: A Case Report.

Matteo Bellia, Riccardo Moia, Mattia Schipani, Carola Sella, Mariangela Greco, Wael Al Essa, Abdurraouf Mokhtar Mahmoud, Gianluca Gaidano, Andrea Patriarca

Abstract read
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matteo BelliaDivision of Hematology, Department of Translational Medicine Universita' del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore Della Carità Novara Italy.ORCID https://orcid.org/0009-0004-9709-4935
Riccardo MoiaDivision of Hematology, Department of Translational Medicine Universita' del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore Della Carità Novara Italy.ORCID https://orcid.org/0000-0001-7393-1138
Mattia SchipaniDivision of Hematology, Department of Translational Medicine Universita' del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore Della Carità Novara Italy.
Carola SellaDivision of Hematology, Department of Translational Medicine Universita' del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore Della Carità Novara Italy.
Mariangela GrecoDivision of Hematology, Department of Translational Medicine Universita' del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore Della Carità Novara Italy.
Wael Al EssaDivision of Hematology, Department of Translational Medicine Universita' del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore Della Carità Novara Italy.
Abdurraouf Mokhtar MahmoudDivision of Hematology, Department of Translational Medicine Universita' del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore Della Carità Novara Italy.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine Universita' del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore Della Carità Novara Italy.
Andrea PatriarcaDivision of Hematology, Department of Translational Medicine Universita' del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore Della Carità Novara Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Managing immune thrombocytopenia (ITP) in HIV patients remains challenging due to refractory cases and treatment limitations. This report highlights fostamatinib as a safe, effective, and antiretroviral therapy-compatible option, offering durable platelet stabilization in a difficult-to-treat population.

Indexed as

ARTfostamatinibHIV infectionimmune thrombocytopenia

Identifiers

PMID40586049
PMCPMC12202462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.